UPCC 09826: A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)

Study of Investigational Medication for Low Grade Upper Tract Urothelial Carcinoma

Enrolling By Invitation
99 years or below
All
Phase N/A
10 participants needed
1 Location

Brief description of study

This is an open-label, multi-center study to determine the efficacy, safety and tolerability of dabogratinib in participants with low-grade, upper tract urothelial carcinoma (LG UTUC).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

The purpose of this study is to investigate low grade upper tract urothelial carcinoma.

This study evaluates the efficacy, safety, and tolerability of an investigational medication.

  • Who can participate: Participants must meet certain age criteria and other eligibility factors, which will be provided later.
  • Study details: Participants will receive an investigational medication. The study will monitor safety and effectiveness. An inactive substance that looks like the investigational medicine but does not contain any medicine may be used as a placebo.
Updated on 13 Aug 2026. Study ID: 26-6276
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator